期刊文献+

高效价血浆在重症腺病毒肺炎患儿中的应用效果

Effect of high Titer Plasma on Children with severe Adenovirus Pneumonia
下载PDF
导出
摘要 目的 探究高效价血浆在重症腺病毒肺炎患儿中的应用效果。方法 回顾性分析2018年1月至2019年12月郑州大学附属儿童医院收治的92例重症腺病毒肺炎患儿,按照治疗方式将患儿分为非高效价血浆组和高效价血浆组,分别为51例、41例。非高效价血浆组接受常规治疗,高效价血浆组在常规治疗的基础上接受高效价血浆治疗。观察比较两组患儿的感染指标、血气指标及体温正常时间、有创呼吸机撤离时间、转出PICU时间、出院时间及存活率。结果 与非高效价血浆组相比,治疗前和治疗后高效价血浆组的各项感染指标、血气指标水平比较差异无统计学意义(P> 0.05);与治疗前相比,治疗后两组的白细胞水平均升高,中性粒细胞和C反应蛋白水平均降低,差异有统计学意义(P <0.05)。与治疗前相比,治疗后两组的各项血气指标水平均升高,差异有统计学意义(P <0.05)。与非高效价血浆组相比,高效价血浆组的有创呼吸机车里时间、转出PICU时间、出院时间差异无统计学意义(P> 0.05),高效价血浆组的体温正常时间缩短,存活率升高,差异有统计学意义(P <0.05)。结论 在重症腺病毒肺炎患儿的治疗中应用高效价血浆,能够有效缩短体温恢复时间,且不会影响感染指标、血气指标及恢复效率,还可提高存活率,临床值得应用。 Objective To investigate the effect of high titer plasma in children with severe adenovirus pneumonia.Methods Retrospective analysis was made on 92 children with severe adenovirus pneumonia admitted to the Affiliated Children's Hospital of Zhengzhou University from January 2018 to December 2019.According to the treatment methods,the children were divided into non-high potency plasma group and high potency plasma group,which were 51 cases and 41 cases respectively.The non-high potency plasma group received routine treatment,while the high potency plasma group received high potency plasma treatment on the basis of routine treatment.The infection index,blood gas index,normal temperature time,invasive ventilator evacuation time,PICU transfer time,discharge time and survival rate were observed and compared between the two groups.Results Compared with the non-high potency plasma group,there was no significant difference in the levels of infection indicators and blood gas indicators between the high potency plasma group before and after treatment(P>0.05);Compared with that before treatment,the level of white blood cells in the two groups increased,while the levels of neutrophils and C-reactive protein decreased after treatment,with a statistically significant difference(P<0.05).Compared with before treatment,the levels of blood gas indexes in the two groups after treatment were significantly higher(P<0.05).Compared with the non-high potency plasma group,there was no statistically significant difference in the invasive breathing time in the high potency plasma group,the time of transferring out of the PICU,and the time of leaving hospital(P>0.05).The normal temperature time in the high potency plasma group was shortened,and the survival rate was increased,with statistically significant differences(P<0.05).Conclusion The application of high titer plasma in the treatment of children with severe adenovirus pneumonia can effectively shorten the temperature recovery time,and will not affect the infection indicators,blood gas indicators and recovery efficiency,but also improve the survival rate,which is worthy of clinical application.
作者 王艳琼 汤昱 董利利 李晓辉 WANG Yanqiong;TANG Yu;DONG Lili;LI Xiaohui(Department of Children's Respiratory,Children's Hospital of Zhengzhou University,Henan Children's Hospital,Zhengzhou Children's Hospital,Zhengzhou Henan 450000,China)
出处 《临床研究》 2022年第12期31-33,共3页 Clinical Research
关键词 高效价血浆 重症腺病毒肺炎 感染指标 血气指标 high potency plasma severe adenovirus pneumonia infection index blood gas index
  • 相关文献

参考文献10

二级参考文献61

  • 1郭立君,邵华,陈子杨,李冰,郭凤云.人巨细胞病毒免疫球蛋白的研制及其临床应用[J].微生物学杂志,2004,24(5):29-30. 被引量:2
  • 2孙朋.小儿呼吸道合胞病毒感染调查分析[J].中国社区医师(医学专业),2006,8(22):49-49. 被引量:2
  • 3邓洁,钱渊,朱汝南,王芳,赵林清.2000年冬-2006年春北京地区急性呼吸道感染患儿中呼吸道合胞病毒的监测[J].中华儿科杂志,2006,44(12):924-927. 被引量:102
  • 4卫生部办公厅.甲型H1N1流感诊疗方案(2009年第3版)[EB/OL].[2009-10-13].http://www.gov.cn/gzdt/2009-10/13/content_1437636.htm.
  • 5TO K K, HUNG 1 F, LI L W, et al. Delayed clearance of viral load and marked cytokine activation in severe cases of pandemic Ht Nl 2009 influenza virus infection [ J]. Clin Infect Dis, 2010, 50(6) : 850 -859.
  • 6NQUYEN H T, TRUJILLO A A, SI-IEU T G, et al. Analysis of influenza viruses from patients clinically suspected of infection with an oseltamivir resistant virus during the 2009 pandemic in the United States[J]. Antivira Res, 2012, 93(3): 381 -386.
  • 7LUKE T C, KILBANE E M, JACKSON J L, et al. Meta- analy- sis: convalescent blood products for spanish influenza pneumonia: a future HsN1 treatment? [J]. Ann Intern Med, 2006, 145(8) : 599 - 609.
  • 8HUNG I F, TO K K, LEE C K, et al. Convalescent plasma trent- ment reduced mortality in patients with severe pandemic influenza A(H5N1)2009 virus infection[J]. Clin Infect Dis, 2011, 52 (4) : 447 -456.
  • 9AOKI F Y, HAYDEN F G, DOLIN R. Antiviral drugs ( other than antiretrovirals) [ M]// MANDELL G L, BENNETT J E, DOLIN R, et al. Principlesand Practices of Infectious Diseases. 7th ed. New York: Churchill Livingstone Elsevier, 2009.
  • 10CHAN K H, TO K K, HUNG I F, et al. Differences in antibody responses of individuals with natural infection and those vaccinated against pandemic H1 N1 2009 influenza [ J]. Clin Vaccine Immu- nol, 2011, 18(5) : 865' -873.

共引文献74

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部